Pathway analysis, in silico modeling

Space missions don’t launch without simulations. Clinical trials shouldn’t either.

Translational biology at your fingertips to guide your next-best experiment.

Target Validation

Your no-code, high-fidelity SaaS platform for AI-driven disease simulations.

BioTarget™ Scoring Tool

Disease models to predict target efficacy.

Predictive biomarkers

Omic Signatures™

Predictive biomarkers to identify patient responders.

Data Visualization

Data Exploration Tool

Versatile data visualization suite to transform complex data into actionable biological insights.

Simmunome is with you at every stage of drug development to make go/no-go decisions, with confidence.

BioTarget™ Scoring Tool

Rank target efficacy, in seconds.

  • Rank new drug targets in your pipeline and compare to FDA approved drugs and competitor targets in development.

  • Quantitative and qualitative efficacy ranking of target or combinations of targets.

  • Traceable, verifiable predictions.

  • Identify previously uncharacterized interactions.

  • No Sponsor data required.

Omic Signatures™

Stratify patients for to meet efficacy endpoints, the first time.

  • Accurately stratify patients to find the optimal subgroups for clinical trial enrollment.

  • Contextualization of differentially-expressed genes or proteins in pathways.

  • Identify patient responders and versus treatment-resistant patients.

  • Identify common omic response biomarkers for label expansion.

Why companies choose Simmunome.

Hybrid Approach.

Our unique approach combines mechanistic modeling and ML algorithms. Abiding by biological rules, it surpasses traditional methods and pure data-driven approaches in reliability.

Traceable Predictions.

Enabling researchers to unlock underlying mechanisms of molecular cascades.

Speed & Flexibility.

Development of disease models across various therapeutic areas, allowing for cross-disease comparisons and quick adaptation to the most promising indications.

Patient Stratification Use Case

How next-order biomarkers can identify patients most likely to respond to treatment from resistant patients and save you from a costly Phase III failure.

Latest News

Deep tech company Simmunome selected for prestigious Merck Digital Sciences Studio inaugural Canadian cohort and receives investment.

Library of Disease Models

Library of Disease Models

  • -Breast Cancer

    -Colorectal Cancer

    -NSCLC & SCLC

    -Prostate Cancer

    -Melanoma

    -Diffuse Large B Cell Lymphoma (ABC, GCB)

  • -Alzheimer’s Disease

    -Parkinson’s Disease

    -ALS

  • -Tissue Repair

Don’t see your therapeutic area here? Simmunome can develop disease models for your specific indication. Check in regularly with us to see our growing library.

  • “Working with Simmunome has been a turning point for our target validation strategy at Espoir Biosciences. As we explored a novel therapeutic target for ALS, we needed deeper insight into its biological context and relevance to key ALS-related mechanisms. Simmunome delivered a comprehensive, systems-level analysis that went beyond what we could have achieved internally, predicting key interactors, comparing our target to known ALS-associated genes, and providing tissue- and genotype-specific data that helped shape our research priorities. Their insights helped us guide experiments that align with the most promising biological pathways. We truly appreciated their scientific rigor and the strategic value they brought to our project.”

    — Constantin Bretonneau, CEO & Co-Founder of Espoir Biosciences, (a spinoff of CRCHUM)

  • "Collaborating with Simmunome has been invaluable in identifying novel biomarkers and therapeutic targets for Parkinson’s Disease. Simmunome identified molecular biomarkers from single-cell transcriptomic datasets, distinguishing between healthy controls and Parkinson’s Disease subtypes offering promising new directions for therapies. This is the start of a long relationship to gain deeper insights into the vast amount of data in neurodegenerative diseases at our institute. Simmunome’s work stands out for its scientific precision, transparency, and commitment to translational impact. Their ability to derive biologically meaningful insights from multi-dimensional data has brought immense value to the consortium and set a new benchmark in computational biomarker discovery."

    — Marc Lussier, Executive Director - McGill University Neuro-CERVO Alliance for Drug Discovery in Brain Diseases

+1.3M

Dynamic molecular interactions.

11

Off-the-shelf disease models, readily available.

78%

Of potential failures are detectable at an at an early stage using our tools.

$1.4B

Potential savings, per successful drug.

Collaborate with Simmunome.

Whether you need a turn-key solution for autonomous analysis or a tailored approach, Simmunome partners with you to deliver fast, accurate results, empowering confident go/no-go decisions for your pipeline.

Service

White-glove service for customized solutions.

SaaS

Customer-led upload for autonomous decision making.

You Asked, We Answered

We put together this FAQ video to answer some of the most commonly asked questions about our technology.

🔍 Interested in learning about how AI can make drug development more efficient?

🧬 Curious about what type of clinical data is required?

🔬 Wondering when is the best time to integrate AI in your drug development process?

Mila Quebec Institute for AI

Simmunome believes in the responsible development of AI to benefit humanity.

Simmunome’s members are trained in the TRAIL program. The training program was initiated and designed under the supervision of Yoshua Bengio, Scientific Director at Mila. The program is aimed at teaching AI researchers to implement ethical, legal and governance considerations in their methodology and practices.